Form 4 KALOBIOS PHARMACEUTICALS For: Nov 16 Filed by: Anthion Partners II LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Shock of Epic Short Squeeze in KaloBios Pharma (KBIO) Reverberates Across Wall Street
November 19, 2015 1:36 PM ESTThe stock being talked about the most on trading desks today is KaloBios Pharma (NASDAQ: KBIO). After closing at around $2 per share, shares surged to as high as $21.05 (+953%) following a disclosure after the close from Turing Pharmaceuticals' Martin Shkreli, a man demonized for jacking up drug prices, that he accumulated 1.2 million shares.
$2... $4... $6... $10... $12... shares keep climbing as short sellers were left stunned.
You see, just... More
Anthion Partners II Buys ~700K Shares of KaloBios Pharma (KBIO), Adding to Madness
November 18, 2015 5:39 PM ESTIn addition to the Martin Shkreli buys on KaloBios Pharma (NASDAQ: KBIO) disclosed after the close, Anthion Partners II disclosed it bought 713,726 shares on 11/16 at $1.26-$1.76. Shares are up 700% after-hours.
... More